Evolving Concepts in Treatment for Advanced Breast Cancer

EP. 1: Introduction and Overview of the MONALEESA-7 Trial

July 16th 2019

EP. 2: MONALEESA-2 and Choosing Among the CDK4/6

July 16th 2019

EP. 3: Predictive and Prognostic Biomarkers and Resistance Mutations

July 16th 2019

EP. 4: Treatment After Progression on CDK4/6

July 16th 2019

EP. 5: Implications of Finding Patients With PIK3CA Mutations

July 16th 2019

EP. 6: TAILORx Trial for ER-Positive Patients

July 16th 2019

EP. 7: Trials That Shaped HER2-Positive Therapy for BC

July 16th 2019

EP. 8: Treatment of Homogeneous Tumors vs Heterogenetic Tumors

July 16th 2019

EP. 9: Treatment Options for Metastatic HER2+ Breast Cancer

July 16th 2019

EP. 10: Emerging Agents for Relapsed-Refractory HER2+ MBC

July 16th 2019

EP. 11: Approach to Neoadjuvant Therapy for Triple-Negative Breast Cancer

July 16th 2019

EP. 12: Immunotherapy for Triple-Negative Breast Cancer

July 16th 2019

EP. 13: The Use of Chemotherapy and Checkpoint Inhibitors for TNBC

July 16th 2019

EP. 14: Treatment of Germline BRCA with PARP and Checkpoint

July 16th 2019

EP. 15: Genomic/Somatic Molecular Alteration Evaluation

July 16th 2019

EP. 16: Final Thoughts on the Treatment of Breast Cancer

July 16th 2019